ASX:NEU - Neuren Pharmaceuticals Stock Price, News, & Analysis

-0.03 (-2.59 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
Now: A$1.13
50-Day Range
MA: A$1.17
52-Week Range
Now: A$1.13
Volume44,837 shs
Average VolumeN/A
Market Capitalization$113.19 million
P/E Ratio36.45
Dividend YieldN/A
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. Its lead product is trofinetide, which has completed Phase II clinical trials for the treatment of Rett syndrome; is in Phase II clinical trials for the treatment of Fragile X syndrome; and conducted Phase II clinical trials for the treatment moderate to severe traumatic brain injury. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid syndrome. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9092 0480



Sales & Book Value

Annual Sales$13.99 million
Cash FlowA$0.23 per share
Book ValueA$0.25 per share



Market Cap$113.19 million
Next Earnings DateN/A

Receive NEU News and Ratings via Email

Sign-up to receive the latest news and ratings for NEU and its competitors with MarketBeat's FREE daily newsletter.

Neuren Pharmaceuticals (ASX:NEU) Frequently Asked Questions

What is Neuren Pharmaceuticals' stock symbol?

Neuren Pharmaceuticals trades on the ASX under the ticker symbol "NEU."

Has Neuren Pharmaceuticals been receiving favorable news coverage?

News articles about NEU stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuren Pharmaceuticals earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Neuren Pharmaceuticals.

Who are some of Neuren Pharmaceuticals' key competitors?

Who are Neuren Pharmaceuticals' key executives?

Neuren Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Spencer Treagus BScMed, MBChB, MPharmMed, MBA, Exec. Chairman
  • Mr. Lawrence Glass, Chief Science Officer
  • Mr. Jonathan Charles Pilcher, CFO & Company Sec.

What is Neuren Pharmaceuticals' stock price today?

One share of NEU stock can currently be purchased for approximately A$1.13.

How big of a company is Neuren Pharmaceuticals?

Neuren Pharmaceuticals has a market capitalization of $113.19 million and generates $13.99 million in revenue each year. Neuren Pharmaceuticals employs 8 workers across the globe.View Additional Information About Neuren Pharmaceuticals.

What is Neuren Pharmaceuticals' official website?

The official website for Neuren Pharmaceuticals is

How can I contact Neuren Pharmaceuticals?

The company can be reached via phone at 61 3 9092 0480.

MarketBeat Community Rating for Neuren Pharmaceuticals (ASX NEU)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Neuren Pharmaceuticals and other stocks. Vote "Outperform" if you believe NEU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel